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OBJECTIVES: Currently, no active third-line treatment exists for
patients previously treated for multiple myeloma, who fail to
respond to conventional chemotherapy. A model was developed
to evaluate the costs and beneﬁts of a new proteasome inhibitor,
VELCADE, relative to best supportive care. METHODS: A two-
part mathematical model of survival was applied to individual
patient data from the SUMMIT1 trial, a multi-center phase 2,
single arm trial of adult patients with a life expectancy of more
than three months; in the ﬁrst part the time to disease progres-
sion for patients was estimated; the time from disease progres-
sion till death was estimated in the second part. Several survival
estimation techniques were applied. Resource use data from
SUMMIT were used to estimate costs from the perspective of the
NHS in the UK for VELCADE administration, hospital care,
concomitant medications and diagnostic tests and surgical pro-
cedures on an individual patient basis. RESULTS: By delaying
the rate at which disease progresses, VELCADE produces sur-
vival gains relative to Best Supportive Care that range between
7.75 to 12.09 months of life depending on the assumed survival
proﬁle. Additional costs (2003 prices) of the novel agent were
£17,290 without accounting for additional costs incurred during
the extended period of survival or £24,121 if such costs are
included. Combining these results with various survival estima-
tions yields an incremental cost-effectiveness ratio (ICER) 
for VELCADE in the range of £17,161–£33,539 per life year
gained. CONCLUSION: VELCADE has been licensed in Europe
and hence information with regard to its clinical and cost-
effectiveness is timely. The range of ICER estimates obtained
(£17,000–£33,000 per additional life year) demonstrate cost-
effectiveness of VELCADE as compared with Best Supportive
Care. These ICER estimates compare favourably to other salvage
therapies currently in widespread use throughout the UK.
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OBJECTIVE: To assess the cost-utility of fulvestrant (Faslodex)
as a replacement for exemestane (Aromasin) in the second line
treatment of postmenopausal women with advanced breast
cancer (ABC) in England. METHODS: A Markov model was
developed allowing up to three separate lines of treatment. In the
scenario studied, patients received fulvestrant or exemestane, fol-
lowed by megestrol acetate and then a ﬁnal palliative care
package. The clinical pathways and resource use assumptions
were based on a survey of UK oncologists. The analysis was from
the perspective of the UK National Health Service (NHS) and
estimated the total cost and beneﬁts, including quality adjusted
life years (QALYs), of two patient cohorts. Clinical evidence was
taken from published clinical trials. Unit costs were taken from
nationally published sources and reported in year 2003 prices.
Treatment each month comprised of drug therapy plus other
care, including treatment of adverse events and health care pro-
fessional visits. Costs varied depending on the health state the
patients were in during any month. The time horizon of the
model was 11 years. All costs and QALYs within the model were
discounted at 3.5%. RESULTS: The model was run with a
cohort of 100 patients. When compared against exemestane in
second line treatment, the 100 patients on fulvestrant gained an
extra 8.1 QALYs for an additional cost of £240,705 giving an
incremental cost-effectiveness ratio (ICER) of £29,641 per
QALY. CONCLUSIONS: Fulvestrant is likely to produce addi-
tional beneﬁts compared with exemestane at an acceptable addi-
tional cost, illustrated by the ICER of £29,641 per QALY. The
health beneﬁt gain from fulvestrant was driven primarily by both
a higher proportion of responders and longer time on second line
treatment. The ﬁndings suggest that fulvestrant is a cost-
effective second line option to the NHS in the UK.
PCN5
COST-UTILITY ANALYSIS OF ANASTROZOLE VERSUS
TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL
WOMEN WITH EARLY BREAST CANCER (EBC): A UK
NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
Brown R1, Benedict A1, Mansel RE2
1MEDTAP International Inc, London, UK; 2University of Wales College
of Medicine, Cardiff, UK
OBJECTIVES: This study estimated the incremental cost per
quality adjusted life year (QALY) gained for anastrozole com-
pared with tamoxifen from the UK NHS perspective, based upon
ATAC trial data (Cancer 2003;98:1802–10). In this trial, anas-
trozole demonstrated superior efﬁcacy and tolerability versus
tamoxifen. Cost-effectiveness analysis found that over 25 years
anastrozole had an incremental cost-effectiveness ratio (ICER) of
GBP11,747 per life-year gained (LYG) among the clinically rele-
vant population of patients with hormone receptor-positive
(HR+) EBC. The model was expanded to include patient utilities
to meet NICE and Scottish Medicines Committee preferences for
cost-utility analysis and to facilitate comparisons across disease
areas. METHODS: Patient utilities were elicited from 23 EBC
patients on adjuvant hormonal therapy. Using the standard
gamble technique, health states relating to adverse events reported
in ATAC and breast cancer disease states were compiled and
reviewed by clinicians. Utility values were incorporated into the
cost-effectiveness model projecting outcomes for anastrozole and
tamoxifen to 25 years, based on probability of side effects (ATAC
safety data) and time in a particular health state. All parameters
(including utilities) were varied in sensitivity analyses. QALYs and
unadjusted LYG were compared with cost outcomes. RESULTS:
Patients’ valuation of the different health states ranged from 0.71
to 0.99. Differences between incremental LYG and QALYs for
anastrozole and tamoxifen were similar (0.3). The discounted
ICER of anastrozole compared with tamoxifen was GBP11,506
per QALY gained (95% CI: GBP1771–GBP22,491). CONCLU-
SIONS: The incorporation of mean-adjusted utility values
resulted in only minor improvement in the ICER in favour of
anastrozole. Furthermore, sensitivity analysis showed that the
ICER was robust to changes in utility scores and that the great-
est impact on the ICER remains the improved disease-free sur-
vival with anastrozole. Anastrozole provides QALY gains at
acceptable costs compared with tamoxifen in the adjuvant treat-
ment of postmenopausal women with HR+ EBC.
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